American Bio Medica Corporation (ABMC)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -1.24 Million USD | -5.34% |
| 2021 | -1.17 Million USD | -89.86% |
| 2020 | -621 Thousand USD | -4.72% |
| 2019 | -593 Thousand USD | 22.18% |
| 2018 | -762 Thousand USD | -145.02% |
| 2017 | -311 Thousand USD | -21.01% |
| 2016 | -257 Thousand USD | -13.72% |
| 2015 | -226 Thousand USD | -4.15% |
| 2014 | -217 Thousand USD | 80.81% |
| 2013 | -1.13 Million USD | -21.74% |
| 2012 | -929 Thousand USD | -536.3% |
| 2011 | -146 Thousand USD | 72.66% |
| 2010 | -534 Thousand USD | 20.54% |
| 2009 | -672 Thousand USD | -7.35% |
| 2008 | -626 Thousand USD | 26.87% |
| 2007 | -856 Thousand USD | -441.04% |
| 2006 | 251 Thousand USD | 173.82% |
| 2005 | -340 Thousand USD | -198.27% |
| 2004 | 346 Thousand USD | -60.64% |
| 2003 | 879 Thousand USD | 17.36% |
| 2002 | 749 Thousand USD | 0.0% |
| 2001 | - USD | 100.0% |
| 2000 | -2.07 Million USD | -20.83% |
| 1999 | -1.71 Million USD | 61.8% |
| 1998 | -4.5 Million USD | -554.07% |
| 1997 | -688 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | - USD | 100.0% |
| 2023 Q1 | -212 Thousand USD | 82.93% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q2 | -347 Thousand USD | -4.83% |
| 2022 Q1 | -331 Thousand USD | -49.1% |
| 2022 FY | -1.24 Million USD | -5.34% |
| 2022 Q4 | -1.24 Million USD | -374.05% |
| 2022 Q3 | -262 Thousand USD | 24.5% |
| 2021 Q4 | -222 Thousand USD | -8.82% |
| 2021 FY | -1.17 Million USD | -89.86% |
| 2021 Q1 | -509 Thousand USD | -163.73% |
| 2021 Q2 | -244 Thousand USD | 52.06% |
| 2021 Q3 | -204 Thousand USD | 16.39% |
| 2020 FY | -621 Thousand USD | -4.72% |
| 2020 Q2 | 16 Thousand USD | 105.9% |
| 2020 Q3 | -172 Thousand USD | -1175.0% |
| 2020 Q1 | -271 Thousand USD | -48.09% |
| 2020 Q4 | -193 Thousand USD | -12.21% |
| 2019 Q1 | -174 Thousand USD | 50.0% |
| 2019 Q2 | -155 Thousand USD | 10.92% |
| 2019 Q3 | -81 Thousand USD | 47.74% |
| 2019 Q4 | -183 Thousand USD | -125.93% |
| 2019 FY | -593 Thousand USD | 22.18% |
| 2018 FY | -762 Thousand USD | -145.02% |
| 2018 Q4 | -348 Thousand USD | -163.64% |
| 2018 Q3 | -132 Thousand USD | -78.38% |
| 2018 Q1 | -206 Thousand USD | 9.65% |
| 2018 Q2 | -74 Thousand USD | 64.08% |
| 2017 Q1 | -67 Thousand USD | 44.63% |
| 2017 Q3 | 5000.00 USD | 123.81% |
| 2017 Q4 | -228 Thousand USD | -4660.0% |
| 2017 FY | -311 Thousand USD | -21.01% |
| 2017 Q2 | -21 Thousand USD | 68.66% |
| 2016 Q4 | -121 Thousand USD | -101.67% |
| 2016 FY | -257 Thousand USD | -13.72% |
| 2016 Q1 | -91 Thousand USD | 51.34% |
| 2016 Q2 | 14 Thousand USD | 115.38% |
| 2016 Q3 | -60 Thousand USD | -528.57% |
| 2015 Q4 | -187 Thousand USD | -534.88% |
| 2015 Q2 | -31 Thousand USD | 41.51% |
| 2015 Q3 | 43 Thousand USD | 238.71% |
| 2015 FY | -226 Thousand USD | -4.15% |
| 2015 Q1 | -53 Thousand USD | 70.22% |
| 2014 FY | -217 Thousand USD | 80.81% |
| 2014 Q1 | 62 Thousand USD | 122.88% |
| 2014 Q2 | 23 Thousand USD | -62.9% |
| 2014 Q4 | -178 Thousand USD | -43.55% |
| 2014 Q3 | -124 Thousand USD | -639.13% |
| 2013 Q3 | -286 Thousand USD | -35.55% |
| 2013 Q4 | -271 Thousand USD | 5.24% |
| 2013 FY | -1.13 Million USD | -21.74% |
| 2013 Q2 | -211 Thousand USD | 41.71% |
| 2013 Q1 | -362 Thousand USD | 27.89% |
| 2012 Q4 | -502 Thousand USD | -119.21% |
| 2012 Q3 | -229 Thousand USD | -663.33% |
| 2012 Q2 | -30 Thousand USD | 82.25% |
| 2012 Q1 | -169 Thousand USD | -725.93% |
| 2012 FY | -929 Thousand USD | -536.3% |
| 2011 Q1 | -374 Thousand USD | -28.97% |
| 2011 FY | -146 Thousand USD | 72.66% |
| 2011 Q3 | 26 Thousand USD | -85.14% |
| 2011 Q4 | 27 Thousand USD | 3.85% |
| 2011 Q2 | 175 Thousand USD | 146.79% |
| 2010 Q2 | 222 Thousand USD | 201.37% |
| 2010 FY | -534 Thousand USD | 20.54% |
| 2010 Q4 | -290 Thousand USD | -17.41% |
| 2010 Q3 | -247 Thousand USD | -211.26% |
| 2010 Q1 | -219 Thousand USD | -92.11% |
| 2009 Q3 | -184 Thousand USD | -8.24% |
| 2009 FY | -672 Thousand USD | -7.35% |
| 2009 Q1 | -204 Thousand USD | 63.38% |
| 2009 Q2 | -170 Thousand USD | 16.67% |
| 2009 Q4 | -114 Thousand USD | 38.04% |
| 2008 Q1 | -162 Thousand USD | -2414.29% |
| 2008 FY | -626 Thousand USD | 26.87% |
| 2008 Q2 | -34 Thousand USD | 79.01% |
| 2008 Q4 | -557 Thousand USD | -538.58% |
| 2008 Q3 | 127 Thousand USD | 473.53% |
| 2007 Q3 | -213 Thousand USD | 43.35% |
| 2007 Q4 | 7000.00 USD | 103.29% |
| 2007 FY | -856 Thousand USD | -441.04% |
| 2007 Q1 | -274 Thousand USD | -356.07% |
| 2007 Q2 | -376 Thousand USD | -37.23% |
| 2006 FY | 251 Thousand USD | 173.82% |
| 2006 Q1 | 32 Thousand USD | 103.56% |
| 2006 Q2 | 116 Thousand USD | 262.5% |
| 2006 Q3 | -4000.00 USD | -103.45% |
| 2006 Q4 | 107 Thousand USD | 2775.0% |
| 2005 Q3 | 312 Thousand USD | 85.71% |
| 2005 Q4 | -900 Thousand USD | -388.46% |
| 2005 Q2 | 168 Thousand USD | 136.62% |
| 2005 Q1 | 71 Thousand USD | 220.34% |
| 2005 FY | -340 Thousand USD | -198.27% |
| 2004 Q1 | 38 Thousand USD | -55.29% |
| 2004 Q4 | -59 Thousand USD | -118.91% |
| 2004 Q2 | 55 Thousand USD | 44.74% |
| 2004 Q3 | 312 Thousand USD | 467.27% |
| 2004 FY | 346 Thousand USD | -60.64% |
| 2003 Q2 | 266 Thousand USD | 3055.56% |
| 2003 Q1 | -9000.00 USD | -137.5% |
| 2003 Q4 | 85 Thousand USD | -84.17% |
| 2003 Q3 | 537 Thousand USD | 101.88% |
| 2003 FY | 879 Thousand USD | 17.36% |
| 2002 FY | 749 Thousand USD | 0.0% |
| 2002 Q1 | 11 Thousand USD | 0.0% |
| 2002 Q2 | 246 Thousand USD | 2136.36% |
| 2002 Q3 | 440 Thousand USD | 78.86% |
| 2002 Q4 | 24 Thousand USD | -94.55% |
| 2001 FY | - USD | 100.0% |
| 2001 Q3 | -843 Thousand USD | -293.93% |
| 2001 Q2 | -214 Thousand USD | 76.74% |
| 2001 Q1 | -920 Thousand USD | -69.43% |
| 2000 Q2 | -308 Thousand USD | 79.87% |
| 2000 FY | -2.07 Million USD | -20.83% |
| 2000 Q3 | -619 Thousand USD | -100.97% |
| 2000 Q1 | -1.53 Million USD | -272.26% |
| 2000 Q4 | -543 Thousand USD | 12.28% |
| 1999 Q2 | -106 Thousand USD | 87.32% |
| 1999 Q3 | -30 Thousand USD | 71.7% |
| 1999 FY | -1.71 Million USD | 61.8% |
| 1999 Q4 | -411 Thousand USD | -1270.0% |
| 1999 Q1 | -836 Thousand USD | -40.03% |
| 1998 Q3 | 21 Thousand USD | 106.89% |
| 1998 Q4 | -597 Thousand USD | -2942.86% |
| 1998 FY | -4.5 Million USD | -554.07% |
| 1998 Q1 | -3.7 Million USD | -516.67% |
| 1998 Q2 | -305 Thousand USD | 91.76% |
| 1997 Q4 | -600 Thousand USD | 0.0% |
| 1997 FY | -688 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Arrayit Corporation | -3.62 Million USD | 65.714% |
| Atlantic International Corp. | -5.73 Million USD | 78.334% |
| Biocept, Inc. | -31.98 Million USD | 96.117% |
| Bioqual, Inc. | -19.63 Thousand USD | -6224.473% |
| CardioGenics Holdings Inc | -772.14 Thousand USD | -60.851% |
| DermTech, Inc. | -103.73 Million USD | 98.803% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion USD | 100.05% |
| HTG Molecular Diagnostics, Inc. | -20.82 Million USD | 94.037% |
| iMD Companies, Inc. | -175.44 Thousand USD | -607.91% |
| IDenta Corp. | -1499.00 USD | -82755.237% |
| Interpace Biosciences, Inc. | 2.8 Million USD | 144.294% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 3310.132% |
| InVitro International | -25.33 Thousand USD | -4801.535% |
| Lumos Diagnostics Holdings Limited | -7.12 Million USD | 82.561% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | -2037.252% |
| Medical Imaging Corp. | -819.48 Thousand USD | -51.56% |
| NovelStem International Corp. | -3.52 Million USD | 64.774% |
| Optigenex Inc. | 1.39 Million USD | 189.299% |
| PharmChem, Inc. | 973.14 Thousand USD | 227.627% |
| Proteome Sciences plc | -1.62 Million USD | 23.381% |
| Response Genetics, Inc | -21.37 Million USD | 94.19% |
| Rennova Health, Inc. | -1.4 Million USD | 11.886% |
| RushNet, Inc. | -684.7 Thousand USD | -81.392% |
| ScreenPro Security Inc. | -2.59 Million USD | 52.091% |
| Stella Diagnostics Inc. | -11.42 Million USD | 89.131% |
| StageZero Life Sciences Ltd. | -7.74 Million USD | 83.967% |
| Todos Medical Ltd. | -9.74 Million USD | 87.259% |